GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Capex-to-Revenue

Starton Therapeutics (Starton Therapeutics) Capex-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Starton Therapeutics's Capital Expenditure for the three months ended in Jun. 2023 was $0.00 Mil. Its Revenue for the three months ended in Jun. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Starton Therapeutics Capex-to-Revenue Historical Data

The historical data trend for Starton Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics Capex-to-Revenue Chart

Starton Therapeutics Annual Data
Trend Mar21 Mar22 Mar23
Capex-to-Revenue
- 0.05 -

Starton Therapeutics Quarterly Data
Mar21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23
Capex-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Starton Therapeutics's Capex-to-Revenue

For the Biotechnology subindustry, Starton Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starton Therapeutics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starton Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Starton Therapeutics's Capex-to-Revenue falls into.



Starton Therapeutics Capex-to-Revenue Calculation

Starton Therapeutics's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.017) / 0
=N/A

Starton Therapeutics's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Starton Therapeutics  (NAS:STA) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Starton Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Starton Therapeutics (Starton Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
215 College Road, Suite No.300, Paramus, NJ, USA, 07652
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines